Neurology

Information, Symptoms, Treatments and Resources

Blank

Alzheimer's Disease: Current Concepts & Future Directions

Rating

References

  1. Alzheimer’s Association. 2012 Alzheimer’s Disease Facts and Figures, Alzheimer’s & Dementia.; 8: 131-168.
  2. Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer’s disease. Nature. 2009; 461:916-922.
  3. Verghese PB, Castellano JM, and Holtzman DM. Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurology. 2011, 10:241-252.
  4. Mayeux R. Clinical practice. Early Alzheimer’s disease. N Engl J Med. 2010; 362:2194-2201.
  5. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011; 7:263-269.
  6. Galvin JE, Roe CM, Xiong C, Morris JC. Validity and reliability of the AD8 informant interview in dementia. Neurology. 2006; 67:1942-1948.
  7. Yaffe K, Laffan AM, Harrison SL, Redline S, Spira AP, Ensrud KE, Ancoli-Israel S, Stone KL. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA. 2011; 306:613-619.
  8. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J. Psychiat Res. 1975; 12:189–198.
  9. Katzman R, Brown T, Fukd P, Peck A, Schechter R, Shimmel H. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiat. 1983; 140:734-739.
  10. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment (MoCA©): A Brief Screening Tool For Mild Cognitive Impairment. J Am Geriatr Soc. 2005; 53:695–699.
  11. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001; 56:1143-1153.
  12. Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: A 24-week, randomized, double-blind study. Clin Therapy. 2010; 32:1234-1251.
  13. Areosa Sastre A, Sherriff F, McShane R. Memantine for dementia. The Cochrane Database of Systematic Reviews. 2005; Issue 3. Art. No.: CD003154. DOI: 10.1002/14651858.CD003154.pub4.
  14. Panza F, Frisardi V, Imbimbo BP, Seripa D, Solfrizzi V, Pilotto A. Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer’s disease: the Aβ target at a crossroads. Expert Opin Biol Ther. 2011; 11:679-686.
  15. Ghosh AK, Brindisi M, Tang J. Developing β-secretase inhibitors for treatment of Alzheimer’s disease. J Neurochem. 2012; 120 Suppl 1:71-83.
  16. Wolfe MS. γ-Secretase inhibitors and modulators for Alzheimer’s disease. J Neurochem. 2012; 120 Suppl 1:89-98.
  17. Morris JC, Aisen PS, Bateman RJ, Benzinger TL, Cairns NJ. Et al. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond). 2012; 2:975-984.
  18. Reiman EM, Langbaum JB, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, Quiroz YT, Kosik KS, Lopera F, Tariot PN. Alzheimer’s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis. 2011; 26 Suppl 3:321-329.
  19. Haydar SN, Dunlop J. Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer’s disease. Curr Top Med Chem. 2010; 10:144-152.
  20. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012; 69:29-38.

 

Disclosure: None reported.

 

See also:

 

MedHelp Health Answers